Skip to main content
Year archive

Moberg Pharma — 2020 filings

All 62 regulatory filings released by Moberg Pharma (MOB) in 2020, sourced directly from the official regulator.

62 Filings
2020 Period
2020 filings (62)
Filing Released Lang
Moberg Pharmas företrädesemission om 150 MSEK är fulltecknad och inga emissionsgarantier har utnyttjats
Share Issue/Capital Change
2020-12-23 Swedish
Moberg Pharma’s rights issue of MSEK 150 is fully subscribed and no issue guarantees have been used
Share Issue/Capital Change
2020-12-23 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-12-08 English
Moberg Pharma offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update
2020-12-03 Swedish
Moberg Pharma publishes prospectus relating to the rights issue
Capital/Financing Update
2020-12-03 English
Bulletin from Moberg Pharma’s Extraordinary General Meeting on December 1[st], 2020
Capital/Financing Update
2020-12-01 English
Kommuniké från Moberg Pharmas extra bolagsstämma den 1 december 2020
Share Issue/Capital Change
2020-12-01 Swedish
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Share Issue/Capital Change
2020-11-30 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Share Issue/Capital Change
2020-11-30 English
Moberg Pharma announces the final terms of the fully guaranteed rights issue
Capital/Financing Update
2020-11-27 English
Moberg Pharma offentliggör de slutliga villkoren för den fullt garanterade företrädesemissionen
Share Issue/Capital Change
2020-11-27 Swedish
OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing
Share Issue/Capital Change
2020-11-16 English
OncoZenge säkerställer finansiering om ca 70 MSEK inför avknoppning och särnotering
Share Issue/Capital Change
2020-11-16 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-10 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q3 2020
2020-11-10 English
Moberg Pharma beslutar om fullt garanterad företrädesemission om cirka 150 MSEK
Share Issue/Capital Change
2020-11-06 Swedish
Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million
Capital/Financing Update
2020-11-06 English
Moberg Pharma avser att dela ut och särnotera BupiZenge[®] (BUPI)
Capital/Financing Update
2020-11-06 Swedish
Moberg Pharma intends to distribute and separately list BupiZenge[®] (BUPI)
M&A Activity
2020-11-06 English
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
AGM Information
2020-11-06 English
Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)
AGM Information
2020-11-06 Swedish
Moberg Pharmas valberedning utsedd
Board/Management Information
2020-11-05 Swedish
Moberg Pharma’s nomination committee appointed
Board/Management Information
2020-11-05 English
Moberg Pharma’s Interim report for July 2019 - September 2020 to be published on November 10 - Invitation to teleconference
Report Publication Announcement
2020-11-03 English
Moberg Pharmas delårsrapport för juli 2019 - september 2020 presenteras 10 november - Inbjudan till telefonkonferens
Report Publication Announcement
2020-11-03 Swedish
Moberg Pharma intends to submit a registration application in Europe in 2021
Regulatory Filings
2020-10-14 English
Moberg Pharma avser att lämna in en registreringsansökan i Europa under 2021
Regulatory Filings
2020-10-14 Swedish
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2020-09-30 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Share Issue/Capital Change
2020-09-30 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-11 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-11 English
Moberg Pharma’s Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference
Report Publication Announcement
2020-08-04 English
Moberg Pharmas delårsrapport för juli 2019 - juni 2020 presenteras 11 augusti - Inbjudan till telefonkonferens
Report Publication Announcement
2020-08-04 Swedish
Moberg Pharma utser ny Chief Medical Officer
Board/Management Information
2020-07-30 Swedish
Appointment of Chief Medical Officer at Moberg Pharma
Board/Management Information
2020-07-30 English
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Share Issue/Capital Change
2020-06-30 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2020-06-30 English
Moberg Pharma meets primary endpoint in the European Phase 3 study
Regulatory Filings
2020-06-25 English
Moberg Pharma uppnår det primära behandlingsmålet i den europeiska fas 3 studien
Regulatory Filings
2020-06-25 Swedish
New number of shares and votes in Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2020-05-29 English
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2020-05-29 Swedish
The board of directors exercises authorizations to issue and repurchase C-shares
Share Issue/Capital Change
2020-05-19 English
Styrelsen utnyttjar emissions- och återköpsbemyndiganden
Share Issue/Capital Change
2020-05-19 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-12 Swedish
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements
2020-05-11 English
Moberg Pharmas delårsrapport för juli 2019 - mars 2020 presenteras 12 maj - Inbjudan till telefonkonferens
Report Publication Announcement
2020-05-05 Swedish
Moberg Pharma’s Interim report for July 2019 - March 2020 to be published on May 12 - Invitation to teleconference
Report Publication Announcement
2020-05-05 English
Kommuniké från Moberg Pharmas extra bolagsstämma den 28 april 2020
AGM Information
2020-04-28 Swedish
Bulletin from Moberg Pharma’s Extraordinary General Meeting on April 28[th], 2020
AGM Information
2020-04-28 English
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
AGM Information
2020-03-27 English
Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)
AGM Information
2020-03-27 Swedish
Moberg Pharma enters financing agreement of up to SEK 216 million for further investments in MOB-015
Capital/Financing Update
2020-03-23 English
Moberg Pharma ingår finansieringsavtal om upp till 216 MSEK för fortsatt satsning på MOB-015
Capital/Financing Update
2020-03-23 Swedish
Earnings Release 2020
Earnings Release H2 2020
2020-02-11 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H2 2020
2020-02-11 English
Moberg Pharma’s Interim report to be published on February 11 - Invitation to teleconference
Report Publication Announcement H2 2020
2020-02-04 English
Moberg Pharmas delårsrapport presenteras 11 februari - Inbjudan till telefonkonferens
Report Publication Announcement
2020-02-04 Swedish
Expertutvärdering förklarar Fas 3 resultat och ger starkt stöd för MOB-015
Regulatory Filings
2020-01-22 Swedish
Expert evaluation clarifies Phase 3 results and provides strong support for MOB-015
Regulatory Filings
2020-01-22 English
Skatteverket meddelar fördelning av anskaffningsutgift för aktier med anledning av inlösen av aktier i Moberg Pharma AB mot kontantlikvid
Notice of Dividend Amount
2020-01-14 Swedish
The Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares due to the redemption in 2019 of shares in Moberg Pharma AB for cash
Notice of Dividend Amount
2020-01-14 English